Syndax Pharmaceuticals Inc (SNDX)
22.05
+0.19
(+0.87%)
USD |
NASDAQ |
May 03, 16:00
22.04
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Research and Development Expense (Annual): 163.03M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 163.03M |
| December 31, 2022 | 118.50M |
| December 31, 2021 | 88.25M |
| December 31, 2020 | 50.44M |
| December 31, 2019 | 42.99M |
| December 31, 2018 | 60.11M |
| Date | Value |
|---|---|
| December 31, 2017 | 48.20M |
| December 31, 2016 | 31.66M |
| December 31, 2015 | 9.549M |
| December 31, 2014 | 10.18M |
| December 31, 2013 | 3.208M |
| December 31, 2012 | 5.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
42.99M
Minimum
2019
163.03M
Maximum
2023
92.64M
Average
88.25M
Median
2021
Research and Development Expense (Annual) Benchmarks
| SpringWorks Therapeutics Inc | 150.49M |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Geron Corp | 125.05M |
| Ionis Pharmaceuticals Inc | 899.62M |
| Madrigal Pharmaceuticals Inc | 272.35M |